1 – 100 of 142
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
-
Mark
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
- 2023
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
2023) In Annals of Neurology(
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
Polygenic risk of type 2 diabetes is associated with incident vascular dementia : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
-
Mark
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
(
- Contribution to journal › Article
-
Mark
‘Proactive aging’ is a new research approach for a new era
(
- Contribution to journal › Letter
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
MRI BrainAGE demonstrates increased brain aging in systemic lupus erythematosus patients
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
The genetic regulation of protein expression in cerebrospinal fluid
(
- Contribution to journal › Article
- 2022
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Decreased Pain Sensitivity and Alterations of Cerebrospinal Fluid and Plasma Inflammatory Mediators After Total Hip Arthroplasty in Patients with Disabling Osteoarthritis
(
- Contribution to journal › Article
-
Mark
Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus
(
- Contribution to journal › Article
-
Mark
Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading
(
- Contribution to journal › Article
-
Mark
β-Amyloid-Dependent and-Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Tau PET Imaging in Neurodegenerative Disorders
2022) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 63. p.20-26(
- Contribution to journal › Article
-
Mark
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease : Long-Term Observation and Implications of Clinical Subtypes
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE 4 carriers
(
- Contribution to journal › Article
-
Mark
Association of β-Amyloid Accumulation with Executive Function in Adults with Unimpaired Cognition
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Hippocampal subregional thinning related to tau pathology in early stages of Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum
(
- Contribution to journal › Article
-
Mark
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain : associations with pain severity and central sensitization
(
- Contribution to journal › Article
-
Mark
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Components of gait in people with and without mild cognitive impairment
(
- Contribution to journal › Article
- 2021
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and diseases
2021)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
2021)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment
(
- Contribution to journal › Article
-
Mark
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article
-
Mark
Sex differences in off-target binding using tau positron emission tomography
(
- Contribution to journal › Article
-
Mark
The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
- 2020
-
Mark
Alcohol Consumption and Risk of Parkinson's Disease : Data from a Large Prospective European Cohort
(
- Contribution to journal › Article
-
Mark
Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding
(
- Contribution to journal › Article
-
Mark
Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment
2020) In European Radiology(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
(
- Contribution to journal › Article
-
Mark
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden
(
- Contribution to journal › Article
- 2019
-
Mark
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
(
- Contribution to journal › Article
-
Mark
Primary fatty amides are potential plasma biomarkers for AD
2019) In Nature Reviews Neurology(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Determining clinically meaningful decline in preclinical Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Low prevalence of known pathogenic mutations in dominant PD genes : A Swedish multicenter study
(
- Contribution to journal › Article
-
Mark
Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia
(
- Contribution to journal › Article
-
Mark
CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Extreme sleep pattern in Lewy body dementia : A hypothalamic matter?
(
- Contribution to journal › Article
-
Mark
Searching for the neurite density with diffusion MRI : Challenges for biophysical modeling
(
- Contribution to journal › Article
-
Mark
18
F-Flortaucipir in TDP-43 associated frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
(
- Contribution to journal › Article
-
Mark
Exploring causality of the association between smoking and Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
(
- Contribution to journal › Article
- 2018
-
Mark
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease : a cohort study
(
- Contribution to journal › Article
-
Mark
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis : A review
(
- Contribution to journal › Scientific review
-
Mark
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
(
- Contribution to journal › Article
-
Mark
Slowly progressive dementia caused by MAPT R406W mutations : Longitudinal report on a new kindred and systematic review
(
- Contribution to journal › Article
-
Mark
Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia
(
- Contribution to journal › Article